DE60019436D1 - Verwendung von nikotin oder derivaten und l-dopa zur behandlung von neurologischen krankheiten, insbesonder morbus parkinson - Google Patents

Verwendung von nikotin oder derivaten und l-dopa zur behandlung von neurologischen krankheiten, insbesonder morbus parkinson

Info

Publication number
DE60019436D1
DE60019436D1 DE60019436T DE60019436T DE60019436D1 DE 60019436 D1 DE60019436 D1 DE 60019436D1 DE 60019436 T DE60019436 T DE 60019436T DE 60019436 T DE60019436 T DE 60019436T DE 60019436 D1 DE60019436 D1 DE 60019436D1
Authority
DE
Germany
Prior art keywords
dopa
nicotine
derivatives
treatment
neurological diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60019436T
Other languages
English (en)
Other versions
DE60019436T2 (de
Inventor
Gabriel Villafane
Pierre Cesaro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP filed Critical Assistance Publique Hopitaux de Paris APHP
Application granted granted Critical
Publication of DE60019436D1 publication Critical patent/DE60019436D1/de
Publication of DE60019436T2 publication Critical patent/DE60019436T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DE60019436T 1999-09-02 2000-09-01 Verwendung von nikotin oder derivaten davon und l-dopa in einem medikament zur behandlung von neurologischen erkrankungen, insbesondere der parkinson-erkrankung Expired - Lifetime DE60019436T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9911029 1999-09-02
FR9911029A FR2798065B1 (fr) 1999-09-02 1999-09-02 Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson
PCT/FR2000/002428 WO2001015696A1 (fr) 1999-09-02 2000-09-01 Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson

Publications (2)

Publication Number Publication Date
DE60019436D1 true DE60019436D1 (de) 2005-05-19
DE60019436T2 DE60019436T2 (de) 2006-02-02

Family

ID=9549506

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60019436T Expired - Lifetime DE60019436T2 (de) 1999-09-02 2000-09-01 Verwendung von nikotin oder derivaten davon und l-dopa in einem medikament zur behandlung von neurologischen erkrankungen, insbesondere der parkinson-erkrankung

Country Status (10)

Country Link
US (1) US6911475B1 (de)
EP (1) EP1212060B1 (de)
AT (1) ATE292969T1 (de)
CA (1) CA2383509C (de)
DE (1) DE60019436T2 (de)
DK (1) DK1212060T3 (de)
ES (1) ES2241651T3 (de)
FR (1) FR2798065B1 (de)
PT (1) PT1212060E (de)
WO (1) WO2001015696A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69912808T2 (de) 1999-12-08 2004-09-30 Centre National De La Recherche Scientifique (C.N.R.S.) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
ES2283425T3 (es) * 2000-08-03 2007-11-01 Antares Pharma Ipl Ag Nueva composicion para la administracion transdermica y/o transmucosa de compuestos activos que asegura niveles terapeutiocos adecuados.
US7198801B2 (en) * 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
KR100421585B1 (ko) 2001-10-25 2004-03-09 한국전자통신연구원 시간분할 듀플렉스 시스템에서 이동국의 셀 탐색 시스템및 그 방법
DE10338174A1 (de) 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
MXPA06003316A (es) * 2003-10-10 2006-06-08 Antares Pharma Ipl Ag Formulacion farmaceutica transdermica para minimizar los residuos en la piel.
US7257577B2 (en) * 2004-05-07 2007-08-14 International Business Machines Corporation System, method and service for ranking search results using a modular scoring system
US7780981B2 (en) 2004-09-13 2010-08-24 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8067399B2 (en) * 2005-05-27 2011-11-29 Antares Pharma Ipl Ag Method and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
NZ571460A (en) 2006-04-21 2010-10-29 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2008067991A2 (en) * 2006-12-08 2008-06-12 Antares Pharma Ipl Ag Skin-friendly drug complexes for transdermal administration
KR101122469B1 (ko) * 2007-04-02 2012-07-12 파킨슨즈 인스티튜트 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
AU2011203482B2 (en) * 2007-04-02 2014-09-04 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
CA2841785A1 (en) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions and methods for treatment of symptoms in parkinson's disease patients
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders
US10213586B2 (en) 2015-01-28 2019-02-26 Chrono Therapeutics Inc. Drug delivery methods and systems
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
US10143687B2 (en) 2016-04-11 2018-12-04 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
US10292977B2 (en) 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
AU2018205529B2 (en) 2017-01-06 2023-08-10 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242935A (en) 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5232933A (en) * 1992-05-21 1993-08-03 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases

Also Published As

Publication number Publication date
DK1212060T3 (da) 2005-08-15
CA2383509A1 (fr) 2001-03-08
ES2241651T3 (es) 2005-11-01
WO2001015696A1 (fr) 2001-03-08
PT1212060E (pt) 2005-08-31
US6911475B1 (en) 2005-06-28
ATE292969T1 (de) 2005-04-15
DE60019436T2 (de) 2006-02-02
EP1212060B1 (de) 2005-04-13
FR2798065B1 (fr) 2003-09-05
CA2383509C (fr) 2012-08-14
FR2798065A1 (fr) 2001-03-09
EP1212060A1 (de) 2002-06-12

Similar Documents

Publication Publication Date Title
DE60019436D1 (de) Verwendung von nikotin oder derivaten und l-dopa zur behandlung von neurologischen krankheiten, insbesonder morbus parkinson
NL970006I1 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
DE60022021D1 (de) Zubereitungen enthaltend Apomorphin und Sildenafil und ihre Verwendung zur Behandlung von erektiler Dysfunktion
MXPA03010402A (es) Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina.
WO2001039763A3 (en) Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
TW200607511A (en) Use of optically pure (S,S)-reboxetine in the manufacture of a medicament for the treatment or prevention of peripheral neuropathy
MXPA05012810A (es) Formas de dosis oral de memantina.
EP1201246A3 (de) Verwendung von Thrombopoietin als Medikament zur Therapie und Vorbeugung der Thrombocytopenie
GB9504329D0 (en) Use of norastemizole for the treatment of allergic disorders
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
PT1689404E (pt) Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
IL194500A0 (en) Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application
RU2003127718A (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
MY132437A (en) New applications of lysozyme dimer
LT2006024A (en) Tetrapeptide regulating blood glucose level in diabetes mellitus
WO1996030016A3 (en) Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases
JPH10506097A (ja) Ｊｅｔ ｌａｇを緩和するための方法と医薬
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
HUP0301119A2 (hu) Bioaktiváló hatóanyag és gyógyszerkészítmény
EP1632235A3 (de) Verwendung von hochselektiven Norepinephrin-Aufnahme-Inhibitoren zur Behandlung von mentalen Erkrankungen
HUP0204116A2 (hu) Eljárások az alacsony termet homeboxát tartalmazó (SHOX) génnel kapcsolatos alacsony termet növekedési rendellenességek kezelésére
EP1797884A3 (de) Verwendung von Taurolidin oder Taurultam zur Herstellung eines Medikaments zur Behandlung von Tumoren des zentralen Nervensystems
MD1568G2 (ro) Metodă de tratament al bolii arşilor în perioada şocului combustional
RU99104174A (ru) Лечение психотических расстройств

Legal Events

Date Code Title Description
8364 No opposition during term of opposition